Ion Beam Applications SA
Olivier Legrain is the current CEO at Ion Beam Applications SA. Olivier has also served as president for iba molecular and iba dosimetry gmbh, as well as chief executive officer for scanditronix medical. In addition, they have been with iba in various capacities since 1996, including chief strategy officer from 2011 to 2012.
Born in 1963, Olivier Legrain graduated from the Hautes Etudes Commerciales de Paris in 1986. Olivier began their career at Arthur Andersen & Co. before joining iba in 1996. Olivier has been instrumental in iba's growth and expansion over the years, helping to make it the world leader in proton therapy that it is today.
Olivier Legrain attended college at the Cardinal Mercier School.
Soumya Chandramouli - Chief Financial Officer, Yves Jongen - Founder & Chief Research Officer, and Frédéric Nolf - Chief Human Resources & Sustainability Officer report to Olivier Legrain.
This person is not in any offices
Ion Beam Applications SA
4 followers
Ion Beam Applications SA (IBA) is a Belgium-based company that develops and markets technologies, pharmaceutical products and tailored solutions for the healthcare sector, with emphasis on cancer diagnosis and therapy. IBA is also active in the sterilization and ionization field. The Company operates through two business segments, namely the pharmaceuticals segment, which includes radiopharmaceuticals and the equipments segment, which encompasses proton therapy, particle accelerators and dosimetry. Through its various subsidiaries, Ion Beam Applications SA is active in a number of countries, including Belgium, Germany, France, Italy, Spain, the United Kingdom, Sweden, the United States, India and China. In November 2013, the Company announced the closing of the sale of 100% of its business unit Cisbio Bioassays.